Sign in
Not yet recruitingPhase 1

Safety of HW281171 tablets in healthy adults, studied for chronic urticaria

Tests how safe HW281171 tablets are and how the body handles them in healthy adults.

Key facts

Who runs it
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Phase I Study of HW281171 Tablets in Healthy Participants
Status
Not yet recruiting
Phase
Phase 1
People taking part
80 people, planned
Started
18 Nov 2026
Expected to end
Sept 2027
Type of study
Interventional, 6 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • HW281171 tablets
  • Placebo tablets
Record updated
17 November 2026

Who can take part

Age
18 years to 45 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Participants sign the informed consent form prior to the initiation of any study procedures
  • Healthy male and female participants aged 18 to 45 years (inclusive), with no less than 3 participants of a single gender
  • Female participants have a body weight of ≥45.00 kg, male participants have a body weight of ≥50.00 kg, and the body mass index (BMI) ranges from 19.0 to 26.0 kg/m\^2 (inclusive)
  • Participants whose vital signs, physical examination, 12-lead electrocardiogram, laboratory tests, abdominal B-ultrasound and posteroanterior chest X-ray results at screening or on Day -1 are judged by the Investigator to be normal or abnormal without clinical significance
  • Participants agree to have no fertility plan and no sperm/egg donation plan from the time of signing the informed consent form until 3 months after study withdrawal, and are willing to practice abstinence or use highly effective contraceptive methods during this period
  • Participants can communicate well with the Investigator, understand and comply with all requirements of this study, and fully understand the study purpose, nature, methods and potential Adverse Events

Who cannot take part

  • Participants with a history of drug or food allergy, allergic diseases, or allergic diathesis (allergic to two or more substances), or with confirmed allergy to any component or analogue of the investigational product
  • Female participants who are pregnant, lactating at screening or during the trial, or have a pregnancy test result above the upper limit of normal, or have had unprotected sexual intercourse within 2 weeks before screening
  • Participants with prior or concomitant medications/non-drug interventions specified in the protocol
  • Participants who have participated in any clinical trial of drugs or medical devices within 90 days before screening (participation in a clinical trial is defined as receiving or using the investigational drug/device)
  • Participants with severe trauma or surgical operation within 3 months before screening; participants who plan to receive surgery during the trial or within two weeks after trial completion
  • Participants who have donated blood or experienced a total blood loss of ≥400 ml within 3 months before the first dose
  • Participants with a smoking history within 3 months before screening (average daily consumption >5 cigarettes), or who cannot stop using any tobacco products during the trial
  • Participants with an average weekly alcohol intake of more than 14 alcohol units within 3 months before screening (1 alcohol unit is approximately 360 ml beer, or 45 ml spirits with 40 Percentage alcohol content, or 150 ml wine), or positive alcohol breath test, or who cannot abstain from alcohol during the trial
  • Participants consuming excessive tea, coffee or caffeinated beverages on average every day (more than 8 cups, 1 cup = 250 ml) within 48 hours before the first dose, or who cannot stop consuming tea, coffee or caffeinated beverages during the trial; participants who have consumed special diets within 48 hours before the first dose (including pitaya, mango, lime, pomelo, carambola, orange, grapefruit or grapefruit products and other fruits or corresponding juices that may affect drug metabolism), or other special diets affecting drug absorption, distribution, metabolism or excretion
  • Participants with any past or current clinically significant severe or chronic diseases of the circulatory, endocrine, nervous, digestive, respiratory, hematological, immune, psychiatric systems or metabolic disorders, or any other diseases judged by the investigator that may interfere with trial results
  • Participants with a history of gastrointestinal, hepatic or renal diseases affecting drug absorption or metabolism, or known or suspected diseases affecting drug intake, transport, absorption, distribution, metabolism or excretion; participants who have undergone surgeries affecting drug absorption or metabolism (appendectomy excluded)
  • Participants with a history of drug abuse, drug dependence, or positive drug screening results
  • Participants with positive results for any of human immunodeficiency virus antibody, hepatitis B virus surface antigen, hepatitis C virus antibody, or treponema pallidum specific antibody
  • Participants with abnormal examination results specified in the protocol at screening or on Day -1
  • Participants with difficult venous access and intolerance to venipuncture
  • Participants with special dietary requirements and unable to follow the unified diet
  • Participants with other factors judged by the investigator to be unsuitable for participating in the clinical trial

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 45 years old?

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This phase 1 study aims to evaluate the safety, tolerability and pharmacokinetic profiles of HW281171 in healthy Participants. The study consists of three parts: Part A (Single-Dose Escalation Study), Part B (Food Effect and Metabolite Study), and Part C (Multiple-Dose Escalation Study).

The 6 groups in the trial

  • Part A:HW281171Treatment being tested

    Single dose of HW281171 tablets

    Treatment: HW281171 tablets

  • Part A:PlaceboPlacebo, for comparison

    Single dose of Placebo tablets

    Treatment: Placebo tablets

  • Part B:Sequence ATreatment being tested

    Single dose of HW281171 tablets under fasting-fed sequence

    Treatment: HW281171 tablets

  • Part B:Sequence BTreatment being tested

    Single dose of HW281171 tablets under fed-fasting sequence

    Treatment: HW281171 tablets

  • Part C:HW281171Treatment being tested

    Multiple doses of HW281171 tablets

    Treatment: HW281171 tablets

  • Part C:PlaceboPlacebo, for comparison

    Multiple doses of Placebo tablets

    Treatment: Placebo tablets

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Profiles of Single and Multiple Oral Administration and Dose Escalation of HW281171 Tablets in Healthy Participants
Plain-language title
Safety of HW281171 tablets in healthy adults, studied for chronic urticariaGenerated from the registry record. The registry title is the official one.
Criteria questions
Built from NCT07936032, who can take part
Record updated
17 November 2026